EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAntonis Fanouriakis, Dimitrios T. Boumpas, Chi Chiu Mok et al.|Annals of the Rheumatic Diseases|2023Cited by 913
Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceRonald van Vollenhoven, Matthias Schneider, Marta Mosca et al.|Annals of the Rheumatic Diseases|2014Cited by 726
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Ronald van Vollenhoven, Murray B. Urowitz, Alexandre E. Voskuyl et al.|Annals of the Rheumatic Diseases|2016Cited by 355
2021 DORIS definition of remission in SLE: final recommendations from an international task forceRonald van Vollenhoven, Y K Onno Teng, George Βertsias et al.|Lupus Science & Medicine|2021Cited by 340
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> TrialEric F. Morand, Shalabh Singhal, Marilyn C. Pike et al.|Arthritis & Rheumatology|2022Cited by 246